Q-omics provides the consensus-scored NTNG1 profile across patient tissues and cancer cell-line models. NTNG1 expression is associated with patient survival in 27 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, NTNG1 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, NTNG1 RNA expression shows 13,084 significant gene co-expression associations, with the highest sampling consensus in KIRP. Together, these results highlight KIRC, and KIRP as cancer lineages where NTNG1 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for NTNG1 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes NTNG1 survival associations across molecular data types. NTNG1 RNA expression shows survival associations in the most cancer types (27), followed by mutation status (8). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible NTNG1 RNA expression–survival associations across cancer types. High NTNG1 expression shows unfavorable associations in KIRC, BLCA, UCEC, LGG, LUSC and STAD. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for NTNG1 RNA expression.
This table summarizes NTNG1 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for NTNG1. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. NTNG1 shows lower tumor expression in KIRC, KIRP, LUAD, BLCA, LUSC and COAD. The KIRC box plot shows higher NTNG1 RNA expression in normal versus tumor tissue (log2 FC = −2.725, t-test p < 0.001).
This table shows molecular features associated with NTNG1 in patient tissues and cancer cell lines. In patient samples, NTNG1 shows the broadest associations at the RNA and protein expression levels, with KIRP recurring as the lineage with the largest associated feature set. In cancer cell lines, NTNG1 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in BREAST, while CRISPR and shRNA rows add functional-dependency signals in SOFT_TISSUE and LARGE_INTESTINE.
